
|Articles|May 1, 2004
Microplasmin receives orphan drug protection
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
Long-lived Greenland sharks may point to new approaches for retinal disease
4
IRIS Registry data mined for understanding of pediatric NK
5












































